Temporary paralysis in Parkinson's disease

Visuel du produit
Apomorphine
Présentation du produit
Colonne 1

temporary paralysis in Parkinson's disease

Colonne 1

Parkinson's disease affects 6.3 million people worldwide, including 1.2 million in Europe and 700,000 in the USA (1).
It is the second most-frequent neurodegenerative disorder after Alzheimer's disease.

Colonne 2

With the world's population aging, the number of patients with Parkinson's disease is expected to double over the next thirty years.
The disease's chronic effects are due to the progressive breakdown of certain nerve cells in the brain.

 

Colonne 3

The efficacy of the most frequently used treatments diminishes over time. When that occurs, patients may start experiencing "off episodes", that is, a period when the symptoms of difficult or impossible ("freezing") movement return.

(1) Epda : www.epda.eu.com